Hiroki Ishihara

Hiroki Ishihara

Auto-generated profile, based on publicly available information

Hiroki Ishihara

Department of Urology Tokyo Women's Medical University Shinjuku‐ku Tokyo Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
HIHiroki Ishihara
Hiroki Ishihara
TTToshio Takagi
Toshio Takagi
TKTsunenori Kondo
Tsunenori Kondo
CHChie Homma
Chie Homma
HTHidekazu Tachibana
Hidekazu Tachibana
KTKazunari Tanabe
Kazunari Tanabe

29 July 2019 in Targeted Oncology
Verified
Journal Article
Closed access
PDF file
HIHiroki Ishihara
Hiroki Ishihara
HTHidekazu Tachibana
Hidekazu Tachibana
TTToshio Takagi
Toshio Takagi
TKTsunenori Kondo
Tsunenori Kondo
HFHironori Fukuda
Hironori Fukuda
KTKazunari Tanabe
Kazunari Tanabe

29 March 2016 in Targeted Oncology
Verified
Journal Article
Closed access
PDF file
HIHiroki Ishihara
Hiroki Ishihara
TKTsunenori Kondo
Tsunenori Kondo
KOKenji Omae
Kenji Omae
TTToshio Takagi
Toshio Takagi
JIJumpei Iizuka
Jumpei Iizuka
KTKazunari Tanabe
Kazunari Tanabe

6 September 2018 in Pathology International
Verified
Journal Article
Open access
PDF file
TKTsunenori Kondo
Tsunenori Kondo
NSNaoto Sasa
Naoto Sasa
HYHiroshi Yamada
Hiroshi Yamada
TTToshio Takagi
Toshio Takagi
JIJunpei Iizuka
Junpei Iizuka
TTToyonori Tsuzuki
Toyonori Tsuzuki
New pathological subtypes of renal cell carcinoma (RCC) were designated in the 2016 World Health Organization (WHO) classification corresponding to the features commonly seen in patients with end‐stage renal disease (ESRD). To determine the clinicopathological findings of new subtypes, we reanalyzed all sections from 315 kidneys in 291 ESRD patients bearing RCC tumors surgically resected in three Japanese institutes by the central pathologist. Clear cell RCC was diagnosed in 144 kidneys (45.7%), acquired cystic disease (ACD)‐associated RCC in 100 (31.7%), papillary RCC in 41 (13.0%), and other minor subtypes in 30 (9.52%). Multivariate analysis showed that longer duration of dialysis, young age, and male sex were independent prognostic clinical factors for the occurrence of ACD‐associated RCC. ACD‐associated RCC included more WHO/International Society of Urologic Pathology (ISUP) grade 3/4 cases compared to other RCCs. In contrast, other unfavorable findings were less frequent in ACD‐associated RCC, including the presence of a sarcomatoid component, lymphovascular invasion, and necrosis. In conclusion, ACD‐associated RCC is a common histology in Japanese patients with ESRD. In addition, ACD‐associated RCC showed more cases with a higher WHO/ISUP grade, but fewer cases with other unfavorable pathological features, suggesting a favorable prognosis of ACD‐associated RCC.

1 September 2017 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
HIHiroki Ishihara
Hiroki Ishihara
TKTsunenori Kondo
Tsunenori Kondo
KYKazuhiko Yoshida
Kazuhiko Yoshida
KOKenji Omae
Kenji Omae
TTToshio Takagi
Toshio Takagi
KTKazunari Tanabe
Kazunari Tanabe

15 July 2016 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HIHiroki Ishihara
Hiroki Ishihara
TKTsunenori Kondo
Tsunenori Kondo
KOKenji Omae
Kenji Omae
TTToshio Takagi
Toshio Takagi
JIJunpei Iizuka
Junpei Iizuka
KTKazunari Tanabe
Kazunari Tanabe